# National Cancer Centre Singapore

Source: https://onco.cc/institutions/nccs/  
OnCo record `nccs` (Institution). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Singapore's national cancer centre and the largest cancer facility in the country, with a proton centre and leading Asian research in liver and lung cancer genomics.

## Summary

The National Cancer Centre Singapore opened in 1999 and moved into a new purpose-built building on the Outram campus in 2023 that houses South-east Asia's first hospital-based proton therapy centre (Goh Cheng Liang Proton Therapy Centre). It treats the majority of Singapore's public-sector cancer patients and, with Duke-NUS Medical School and the Genome Institute of Singapore, has produced influential research on Asian lung cancer in never-smokers, hepatocellular carcinoma and cholangiocarcinoma genomics (including the liver-fluke associated cholangiocarcinoma genome), nasopharyngeal cancer and cancer immunotherapy. NCCS runs the Singapore Translational Cancer Consortium, a large phase 1 unit, and cell therapy programmes with the Singapore Immunology Network, and it coordinates national screening and survivorship initiatives.

## Fields

- Kind: Institution
- Last checked: 2026-09-09
- Also known as: NCCS; SingHealth Duke-NUS Oncology Academic Clinical Programme
- City: Singapore, SG
- Type: cancer-center
- Website: https://www.nccs.com.sg

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/National_Cancer_Centre_Singapore
- National Cancer Centre Singapore: https://www.nccs.com.sg
- Duke-NUS Medical School: https://www.duke-nus.edu.sg
- SingHealth: https://www.singhealth.com.sg
- PTCOG: particle therapy facilities in operation: https://www.ptcog.site/index.php/facilities-in-operation-public

## Connected records

- cancers: [Biliary tract cancer (cholangiocarcinoma)](https://onco.cc/cancers/cholangiocarcinoma/), [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/), [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- fronts: [Cell Therapy](https://onco.cc/fronts/cell-therapy/), [Diagnostics & Biomarkers](https://onco.cc/fronts/diagnostics/), [Radiation Therapy](https://onco.cc/fronts/radiation/)
- technologies: [CAR-T cell therapy](https://onco.cc/technologies/car-t/), [Proton therapy](https://onco.cc/technologies/proton-therapy/), [Proton therapy machines: cyclotrons, synchrotrons and single-room systems](https://onco.cc/technologies/proton-therapy-systems/), [TIL therapy](https://onco.cc/technologies/til-therapy/), [Whole-exome & whole-genome sequencing](https://onco.cc/technologies/wes-wgs/)
- targets: [EGFR](https://onco.cc/targets/egfr/), [FGFR2](https://onco.cc/targets/fgfr2/), [IDH1 / IDH2](https://onco.cc/targets/idh/)
- terms: [Mutational signature](https://onco.cc/terms/mutational-signature/)
- people: [Goh Cheng Liang](https://onco.cc/people/goh-cheng-liang/), [Lim Soon Thye](https://onco.cc/people/lim-soon-thye/), [Rebecca Dent](https://onco.cc/people/rebecca-dent/)
- key papers: [Genomic landscape of lung adenocarcinoma in East Asians](https://onco.cc/key-papers/paper-chen-east-asian-lung-adenocarcinoma-nat-genet-2020/)
- companies: [Hitachi (particle therapy)](https://onco.cc/companies/hitachi/)

---
JSON: https://onco.cc/api/v1/entities/nccs.json